Efficacy and toxicity of antiretroviral therapy using 4 or more agents - Application of a strategy for antiretyoviral management in human immunodeficiency virus-infected children

被引:14
作者
Melvin, AJ
Lewis, PF
Mohan, KM
Naugler, WS
Frenkel, LM
机构
[1] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[2] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[3] Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97201 USA
来源
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE | 2002年 / 156卷 / 06期
关键词
D O I
10.1001/archpedi.156.6.568
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: To characterize the long-term tolerance and virologic efficacy of combination antiretroviral therapy consisting of 4 or more agents in a clinical setting. Methods: An observational review of 36 children infected with human immunodeficiency virus 1 (HIV-1) treated with 4 or 5 antiretroviral agents in 2 university hospital clinics between April 1, 1996, and October 31, 2000. Highly active antiretroviral therapy regimens were chosen with regard to the child's past antiretroviral exposure or results of genotypic resistance data. Plasma HIV-1 RNA levels were monitored weekly to monthly after initiation of highly active antiretroviral therapy, and adherence efforts were actively supported and monitored. Main Outcome Measure: Number of children with undetectable plasma HIV-1 RNA levels at longest followup. Results: Four- or 5-drug highly active antiretroviral therapy reduced plasma HIV-1 RNA levels to less than 50 copies/mL in 32 (89%) of 36 children. After a median of 28.7 months of observation, 28 children (78%) remained at this level of suppression. Adverse reactions were limited to mild neutropenia and mild transient or persistent elevations in alanine aminotransferase levels in 11% of children. Conclusions: Treatment with 4 or 5 antiretroviral agents was well tolerated in HIV-1-infected children and resulted in a high degree of viral suppression, even in children with previous antiretroviral drug experience.
引用
收藏
页码:568 / 573
页数:6
相关论文
共 30 条
[1]   Salvage treatment against human immunodeficiency virus [J].
Battegay, M ;
Harr, T ;
Sponagel, L .
ANNALS OF MEDICINE, 1999, 31 (04) :253-260
[2]   RAPID AND SIMPLE METHOD FOR PURIFICATION OF NUCLEIC-ACIDS [J].
BOOM, R ;
SOL, CJA ;
SALIMANS, MMM ;
JANSEN, CL ;
WERTHEIMVANDILLEN, PME ;
VANDERNOORDAA, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (03) :495-503
[3]   Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment [J].
Bratt, G ;
Karlsson, A ;
Leandersson, AC ;
Albert, J ;
Wahren, B ;
Sandström, E .
AIDS, 1998, 12 (16) :2193-2202
[4]  
BRUNDAGE RC, 2000, 7 C RETR OPP INF JAN
[5]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[6]  
Clevenbergh P, 2000, ANTIVIR THER, V5, P65
[7]  
de Mendoza C, 1999, J HUMAN VIROL, V2, P344
[8]  
DeGruttola V, 2000, ANTIVIR THER, V5, P41
[9]   Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy [J].
Descamps, D ;
Flandre, P ;
Calvez, V ;
Peytavin, G ;
Meiffredy, V ;
Collin, G ;
Delaugerre, C ;
Robert-Delmas, S ;
Bazin, B ;
Aboulker, JP ;
Pialoux, G ;
Raffi, F ;
Brun-Vézinet, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (02) :205-211
[10]   Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].
Durant, J ;
Clevenbergh, P ;
Halfon, P ;
Delgiudice, P ;
Porsin, S ;
Simonet, P ;
Montagne, N ;
Boucher, CAB ;
Schapiro, JM ;
Dellamonica, P .
LANCET, 1999, 353 (9171) :2195-2199